Lymphoma: all 5,624 studies
Page 37 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- Optimal Dose Finding Study ABT-199 and Ibrutinib in MCLCompletedNCT02419560Phase 1
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedNCT02417285Phase 1
- Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or LymphomaTerminatedNCT02414724Phase 1
- Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and DoxorubicinCompletedNCT02414568Phase 2
- Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT02412267Phase 2
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- BNHL-2015 for Children or Adolescents in ChinaActive, not recruitingNCT02405676Phase 2/3
- Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02405078Early Phase 1
- Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation TherapyCompletedNCT02404818
- GDP in Frontline Chemotherapy for Patients With PTCL-NOSStatus unknownNCT02404571Phase 2
- MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System LymphomaStatus unknownNCT02399189Phase 2
- Brentuximab for Newly Diagnosed Hodgkin DiseaseCompletedNCT02398240Phase 2
- A Study Evaluating CPI-1205 in Patients With B-Cell LymphomasCompletedNCT02395601Phase 1
- Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive LymphomaTerminatedNCT02392039Early Phase 1
- First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCLStatus unknownNCT02388581Phase 2
- International Extranodal NK/T-cell Lymphoma ProjectCompletedNCT02386813
- A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and LymphomaCompletedNCT02383368Phase 1
- Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaWithdrawnNCT02378922Phase 1
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL PatientsTerminatedNCT02374424Phase 2
- Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell TherapyCompletedNCT02374333Phase 1
- Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line TherapyStatus unknownNCT02371161Phase 2
- Testing a Personalize Medication Log for Patients With LymphomaCompletedNCT02370446
- Cohort of Peripheral T Cell LymphomaStatus unknownNCT02364466
- Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGMStatus unknownNCT02364050
- Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early StageTerminatedNCT02359162Phase 3
- Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
- An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)Status unknownNCT02354846
- Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult PatientsStatus unknownNCT02354313Phase 3
- A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and LymphomaStatus unknownNCT02349698Phase 1/2
- Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS TumoursCompletedNCT02343718Phase 1
- HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnNCT02343666Phase 1
- A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCompletedNCT02343536Phase 1
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
- Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHLCompletedNCT02342665Phase 1/2
- Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib TreatmentCompletedNCT02341781
- Doxycycline for the Treatment of Cutaneous T-Cell LymphomaTerminatedNCT02341209Phase 2
- Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaCompletedNCT02340936Phase 1/2
- Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGSCompletedNCT02339805Not applicable
- Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell LymphomasTerminatedNCT02323659Phase 4
- A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCLTerminatedNCT02323230Phase 2
- GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02321592Phase 2
- Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesCompletedNCT02315612Phase 1
- Maintenance Treatment Versus Observation in Elderly Patients With PCNS LymphomaStatus unknownNCT02313389Phase 3
- Study of Ibrutinib in Relapsed and Refractory T-cell LymphomaCompletedNCT02309580Phase 1
- Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)CompletedNCT02303119Phase 3
- Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell LymphomaWithdrawnNCT02301494Not applicable
- Detection and Characterization of Residual Masses in LymphomasCompletedNCT02300402
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDCompletedNCT02298283Phase 2
- GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory LymphomaTerminatedNCT02295722Phase 1/2
- Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or LymphomaCompletedNCT02293109Phase 1
- Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.CompletedNCT02292979Phase 2
- ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell TumorsStatus unknownNCT02290132
- Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's TransformationWithdrawnNCT02285244Phase 2
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin LymphomasCompletedNCT02280785Phase 2
- CD19 Redirected Autologous T Cells for Hodgkin LymphomaTerminatedNCT02277522Early Phase 1
- Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell LymphomaCompletedNCT02276248Phase 2
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)Status unknownNCT02274584Phase 1/2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Relaxation and Exercise In Lymphoma PatientsCompletedNCT02272751Not applicable
- Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
- Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTStatus unknownNCT02267915Phase 2
- Tissue Collection for Biomarkers Determining Resistance to IbrutinibStatus unknownNCT02267590
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
- Effects of Anticoagulant Preventive Injection in Patients With Blood CancerCompletedNCT02260414Phase 2
- Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
- COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma PatientsCompletedNCT02253420Phase 1
- Open-Label, Non Randomized Phase 2 Study With Safety Run-InCompletedNCT02249429Phase 2
- Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's LymphomaCompletedNCT02247869Phase 2
- Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell LymphomasStatus unknownNCT02247609Phase 1/2
- BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEVCompletedNCT02244021Phase 2
- Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02243436Phase 1/2
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical PracticeCompletedNCT02240316
- Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive LymphomaStatus unknownNCT02238873Phase 3
- Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi SarcomaWithdrawnNCT02229981Phase 1/2
- Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX ChemotherapyStatus unknownNCT02229682Phase 2
- Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasWithdrawnNCT02228512Phase 1/2
- Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.CompletedNCT02227433Phase 2
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
- Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin LymphomaCompletedNCT02221492Phase 2
- A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaCompletedNCT02220842Phase 1
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
- Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell LymphomaStatus unknownNCT02213861Phase 2
- Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.CompletedNCT02206308Phase 1
- Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life SettingCompletedNCT02199288
- Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)CompletedNCT02192021Phase 1
- Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Tenofovir to Prevent HBV ReactivationStatus unknownNCT02186574Phase 3
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive LymphomasCompletedNCT02181218Phase 1
- Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT02169180Phase 2
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1